Alopecia AreataNCT07803874
UV-Trichoscopic Red Fluorescence in Alopecia Areata
An observational study of Alopecia Areata, run by Istanbul Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata. Trichoscopy is a close-up imaging method used to examine the hair and scalp. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Alopecia Areata
- What is being tested?
- Triamcinolone Acetonide
- How many people
- 40 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jul 2026to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults with limited plaque-type alopecia areata of the scalp who are receiving intralesional corticosteroid treatment as part of routine clinical care at the dermatology outpatient clinic will be prospectively enrolled. Participants will undergo standardized conventional trichoscopic and UV-trichoscopic assessments and will be followed for 12 weeks to evaluate red fluorescence intensity, trichoscopic findings, and hair regrowth.
Who may be able to join
- Age 18 years or older
- Limited plaque-type alopecia areata of the scalp
- Active hair loss
- Symptom onset within the previous 6 months
- No topical, intramuscular, or oral treatment for alopecia areata within the previous 1 month
- No intralesional corticosteroid treatment within the previous 6 weeks
- Provision of informed consent
Who cannot join
- Beard alopecia areata
- Very extensive alopecia areata or multiple large plaques
- Tinea capitis or active infection
- Current phototherapy
- Systemic immunosuppressive treatment within the washout period specified in the study protocol
- Pregnancy or breastfeeding
- Contraindication to UV imaging
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Istanbul Training and Research Hospital
Istanbul
Sevgi Nazli Apucu, Dermatology Resident Physician, +905374048180, snapucu@gmail.com
About this study
Official title: Evaluation of UV-Trichoscopic Red Fluorescence Intensity in Relation to Trichoscopic Findings and Response to Intralesional Corticosteroid Treatment in Limited Plaque-Type Alopecia Areata
The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata. Trichoscopy is a close-up imaging method used to examine the hair and scalp. The study will investigate whether the amount of red fluorescence at the beginning of the study is related to how soon hair starts to grow back, how much hair regrows, and how trichoscopic findings change during follow-up. Participants for whom intralesional corticosteroid treatment has been planned as part of their regular medical care will have standard trichoscopic and UV-trichoscopic images taken of the affected scalp area. They will be followed at weeks 4, 8, and 12, when hair regrowth and changes in scalp and hair findings will be evaluated. Researchers will measure red fluorescence in the images and examine whether it is related to treatment response over time.
Read the detailed description
This is a prospective observational cohort study involving adults with limited plaque-type alopecia areata who are receiving intralesional corticosteroid treatment as part of routine clinical care. Participation in the study does not determine whether a patient receives intralesional corticosteroid treatment.
At baseline, the affected scalp area will be evaluated using conventional polarized trichoscopy and UV-trichoscopy. Follow-up assessments will be performed at weeks 4, 8, and 12 using the same imaging approach. Trichoscopic findings of interest will include yellow dots, black dots, exclamation mark hairs, and broken hairs.
UV-trichoscopic red fluorescence will be assessed quantitatively by measuring red-channel intensity on standardized digital images. Imaging and image analysis procedures will be performed using a standardized acquisition protocol to improve comparability between visits.
Treatment response will be evaluated according to the appearance and extent of visible hair regrowth and the change in trichoscopic activity findings during follow-up. The main analysis will examine whether baseline red fluorescence intensity is associated with the timing and magnitude of response to intralesional corticosteroid treatment. Associations between red fluorescence intensity and baseline trichoscopic findings, as well as changes in fluorescence intensity and trichoscopic findings over time, will also be evaluated.
- Conditions
- Alopecia Areata
- Being tested
- Triamcinolone Acetonide
- Keywords
- UV Trichoscopy, Red Fluorescence, Trichoscopy, Intralesional Corticosteroid, Hair Regrowth
- Medical subject headings
- Alopecia Areata
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Triamcinolone AcetonideDrug
Intralesional triamcinolone acetonide is administered for limited plaque-type alopecia areata as part of routine clinical care. The decision to administer treatment is made independently of participation in this observational study. The study prospectively evaluates trichoscopic and UV-trichoscopic findings and hair regrowth during routine treatment follow-up.
| Study group | Role | What they receive |
|---|---|---|
| Limited Plaque-Type Alopecia Areata | Adults with limited plaque-type alopecia areata who are receiving intralesional corticosteroid treatment as part of routine clinical care. Participants will undergo conventional trichoscopic and UV-trichoscopic assessments at baseline and during follow-up at weeks 4, 8, and 12. Hair regrowth, trichoscopic findings, and UV-trichoscopic red fluorescence intensity will be evaluated over time. Receives: Drug: Triamcinolone Acetonide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Timing of First Visible Hair Regrowth
Baseline UV-trichoscopic red fluorescence intensity will be quantified from standardized digital images using red-channel intensity measurements. Participants will be evaluated for the first appearance of visible hair regrowth at follow-up visits at weeks 4, 8, and 12. The association between baseline red fluorescence intensity and the timing of first visible hair regrowth will be assessed.
Measured: Baseline through week 12
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Degree of Hair Regrowth
The degree of hair regrowth will be assessed at follow-up visits using standardized clinical photographs and trichoscopic images of the alopecic plaque. Hair regrowth will be evaluated according to the proportion of the baseline alopecic area showing visible regrowth, with trichoscopic examination used to identify early or fine regrowing hairs that may not be clearly visible in clinical photographs. The association between baseline UV-trichoscopic red fluorescence intensity and the degree of hair regrowth will be evaluated.
Measured: Weeks 4, 8, and 12
Secondary outcomes (3)
Change in UV-Trichoscopic Red Fluorescence Intensity During Follow-up
UV-trichoscopic red fluorescence intensity will be quantified from standardized digital images using red-channel intensity measurements. Changes in red fluorescence intensity from baseline through follow-up visits will be evaluated
Measured: Baseline and weeks 4, 8, and 12
Change in Area-Normalized Counts of Selected Trichoscopic Findings During Follow-up
Yellow dots, black dots, exclamation mark hairs, and broken hairs will be counted individually on standardized trichoscopic images. Counts will be normalized to the area of the alopecic plaque and expressed as the number of each finding per square centimeter (findings/cm²). Each trichoscopic finding will be analyzed separately rather than combined into a composite severity score. Higher values indicate a greater density of the corresponding finding. For activity-associated findings, including black dots, broken hairs, and exclamation mark hairs, a decrease during follow-up will be interpreted as a reduction in trichoscopic disease activity. Yellow dots will be evaluated separately and will not be interpreted as a direct measure of disease activity.
Measured: Baseline and weeks 4, 8, and 12
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Trichoscopic Findings
The association between baseline UV-trichoscopic red fluorescence intensity and baseline trichoscopic findings, including yellow dots, black dots, exclamation mark hairs, and broken hairs, will be evaluated.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2026
- Study start1 Jul 2026
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alopecia AreataStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istanbul Training and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Sevgi Nazli Apucu, Istanbul Training and Research Hospital
- Investigators
- Vildan Manav, Study chair, Istanbul Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07803874
- Sponsor's protocol ID
- IstanbulTRH-DERM-AAUV-2026
- Status last verified
- Sep 2026
- First submitted
- 31 Aug 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of UV-Trichoscopic Red Fluorescence Intensity in Relation to Trichoscopic Findings and Response to Intralesional Corticosteroid Treatment in Limited Plaque-Type Alopecia Areata
- ClinicalTrials.gov ID
- NCT07803874
- Acronym / sponsor ID
- IstanbulTRH-DERM-AAUV-2026
- Conditions
- Alopecia Areata
- Keywords
- UV Trichoscopy, Red Fluorescence, Trichoscopy, Intralesional Corticosteroid, Hair Regrowth
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Istanbul Training and Research HospitalOther government
- Study start
- 1 Jul 2026 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 4 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn whether red fluorescence seen with ultraviolet (UV) trichoscopy is related to disease findings and treatment response in adults with limited plaque-type alopecia areata. Trichoscopy is a close-up imaging method used to examine the hair and scalp. The study will investigate whether the amount of red fluorescence at the beginning of the study is related to how soon hair starts to grow back, how much hair regrows, and how trichoscopic findings change during follow-up. Participants for whom intralesional corticosteroid treatment has been planned as part of their regular medical care will have standard trichoscopic and UV-trichoscopic images taken of the affected scalp area. They will be followed at weeks 4, 8, and 12, when hair regrowth and changes in scalp and hair findings will be evaluated. Researchers will measure red fluorescence in the images and examine whether it is related to treatment response over time.
Detailed description
This is a prospective observational cohort study involving adults with limited plaque-type alopecia areata who are receiving intralesional corticosteroid treatment as part of routine clinical care. Participation in the study does not determine whether a patient receives intralesional corticosteroid treatment.
At baseline, the affected scalp area will be evaluated using conventional polarized trichoscopy and UV-trichoscopy. Follow-up assessments will be performed at weeks 4, 8, and 12 using the same imaging approach. Trichoscopic findings of interest will include yellow dots, black dots, exclamation mark hairs, and broken hairs.
UV-trichoscopic red fluorescence will be assessed quantitatively by measuring red-channel intensity on standardized digital images. Imaging and image analysis procedures will be performed using a standardized acquisition protocol to improve comparability between visits.
Treatment response will be evaluated according to the appearance and extent of visible hair regrowth and the change in trichoscopic activity findings during follow-up. The main analysis will examine whether baseline red fluorescence intensity is associated with the timing and magnitude of response to intralesional corticosteroid treatment. Associations between red fluorescence intensity and baseline trichoscopic findings, as well as changes in fluorescence intensity and trichoscopic findings over time, will also be evaluated.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Limited Plaque-Type Alopecia Areata | – | Drug: Triamcinolone AcetonideAdults with limited plaque-type alopecia areata who are receiving intralesional corticosteroid treatment as part of routine clinical care. Participants will undergo conventional trichoscopic and UV-trichoscopic assessments at baseline and during follow-up at weeks 4, 8, and 12. Hair regrowth, trichoscopic findings, and UV-trichoscopic red fluorescence intensity will be evaluated over time. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults with limited plaque-type alopecia areata of the scalp who are receiving intralesional corticosteroid treatment as part of routine clinical care at the dermatology outpatient clinic will be prospectively enrolled. Participants will undergo standardized conventional trichoscopic and UV-trichoscopic assessments and will be followed for 12 weeks to evaluate red fluorescence intensity, trichoscopic findings, and hair regrowth.
Key inclusion criteria (7 listed)
- Age 18 years or older
- Limited plaque-type alopecia areata of the scalp
- Active hair loss
- Symptom onset within the previous 6 months
- No topical, intramuscular, or oral treatment for alopecia areata within the previous 1 month
Key exclusion criteria (7 listed)
- Beard alopecia areata
- Very extensive alopecia areata or multiple large plaques
- Tinea capitis or active infection
- Current phototherapy
- Systemic immunosuppressive treatment within the washout period specified in the study protocol
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Triamcinolone AcetonideIntralesional triamcinolone acetonide is administered for limited plaque-type alopecia areata as part of routine clinical care. The decision to administer treatment is made independently of participation in this observational study. The study prospectively evaluates trichoscopic and UV-trichoscopic findings and hair regrowth during routine treatment follow-up. | Drug | Limited Plaque-Type Alopecia Areata |
Primary outcome
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Timing of First Visible Hair Regrowth
Time frame: Baseline through week 12
Baseline UV-trichoscopic red fluorescence intensity will be quantified from standardized digital images using red-channel intensity measurements. Participants will be evaluated for the first appearance of visible hair regrowth at follow-up visits at weeks 4, 8, and 12. The association between baseline red fluorescence intensity and the timing of first visible hair regrowth will be assessed.
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Degree of Hair Regrowth
Time frame: Weeks 4, 8, and 12
The degree of hair regrowth will be assessed at follow-up visits using standardized clinical photographs and trichoscopic images of the alopecic plaque. Hair regrowth will be evaluated according to the proportion of the baseline alopecic area showing visible regrowth, with trichoscopic examination used to identify early or fine regrowing hairs that may not be clearly visible in clinical photographs. The association between baseline UV-trichoscopic red fluorescence intensity and the degree of hair regrowth will be evaluated.
3 secondary outcomes
Change in UV-Trichoscopic Red Fluorescence Intensity During Follow-up
Time frame: Baseline and weeks 4, 8, and 12
Change in Area-Normalized Counts of Selected Trichoscopic Findings During Follow-up
Time frame: Baseline and weeks 4, 8, and 12
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Trichoscopic Findings
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Alopecia Areata
Active, not recruitingPhase 3
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
Severe Alopecia Areata
RecruitingPhase 2
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Active, not recruitingObservational study
Litfulo Capsules Special Investigation
Alopecia Areata
Active, not recruitingObservational study
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
Alopecia Areata
Active, not recruitingObservational study
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vildan Manav study chair
Istanbul Training and Research Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alopecia Areata, run by Istanbul Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sevgi Nazli Apucu, Dermatology Resident Physician (+905374048180, snapucu@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Association Between Baseline UV-Trichoscopic Red Fluorescence Intensity and Timing of First Visible Hair Regrowth (time frame: Baseline through week 12). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026.